Sulfacetamide

CHEMBL455 Phase 4 승인됨 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
214.2 g/mol
LogP
-1.0
Phase
4

Sulfacetamide is a sulfonamide antibiotic used topically in ophthalmic preparations for bacterial conjunctivitis and blepharitis caused by susceptible organisms, and in dermatological preparations for seborrheic dermatitis, rosacea, and acne. By inhibiting bacterial dihydropteroate synthase, it prevents folic acid synthesis in susceptible gram-positive and gram-negative bacteria. Its ophthalmic use is well established due to adequate corneal penetration and a favorable safety profile.

분자량

214.2400 g/mol

LogP

-1.00

TPSA

97.60 Ų

리핀스키 5의 법칙

통과

작용 기전

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

2D 구조

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)NS(=O)(=O)c1ccc(N)cc1

InChI

InChI=1S/C8H10N2O3S/c1-6(11)10-14(12,13)8-4-2-7(9)3-5-8/h2-5H,9H2,1H3,(H,10,11)

Molecular Formula

C8H10N2O3S

HBD / HBA

2 / 4

회전 가능 결합

2

무거운 원자

14

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

Sulfacetamide is a sulfonamide antibiotic used topically in ophthalmic preparations for bacterial conjunctivitis and blepharitis caused by susceptible organisms, and in dermatological preparations for seborrheic dermatitis, rosacea, and acne. By inhibiting bacterial dihydropteroate synthase, it prevents folic acid synthesis in susceptible gram-positive and gram-negative bacteria. Its ophthalmic use is well established due to adequate corneal penetration and a favorable safety profile.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Sulfacetamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL455. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5320. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.